Global Cardiac Rhythm Management Devices Market

Cardiac Rhythm Management Devices Market Size, Share, Growth Analysis, By Product(Pacemakers [Implantable, External], Defibrillators [Implantable Cardioverter Defibrillators (ICD) (S-ICD, T-ICD)), By End User(Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2577 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 59 | Figures: 75

Cardiac Rhythm Management Devices Market Competitive Landscape

Cardiac rhythm management device companies should focus on developing affordable products to maximize their sales in developing countries. Currently, countries with developed healthcare infrastructure provide lucrative business scope for new as well as established cardiac rhythm management device providers. Collaborations, new product launches, mergers, and new product approvals are slated to be key strategies for cardiac rhythm management devices market players in the long run. 

Cardiac Rhythm Management Devices Market Top Player’s Company Profiles

  • Physio-Control, Inc. (Stryker) (US) 
  • BIOTRONIK (Germany) 
  • Schiller (Switzerland) 
  • Medtronic (US) 
  • Abbott (US) 
  • Koninklijke Philips N.V. (Netherlands) 
  • Zoll Medical Corporation (US) 
  • Boston Scientific Corporation (US) 
  • Progetti Srl (Italy) 
  • LivaNova Plc (UK) 
  • Impella (ABIOMED, US) 
  • AngioDynamics, Inc. (US) 
  • MicroPort Scientific Corporation (China) 
  • Edwards Lifesciences Corporation (US) 
  • Getinge AB (Sweden) 
  • Synchrony Medical (US) 
  • Osypka AG (Germany) 
  • Inspire Medical Systems, Inc. (US) 
  • AtriCure, Inc. (US) 
  • Apex Medical (Taiwan) 
  • Biotronik SE & Co. KG (Germany) 
  • VivaSonic Inc. (US)

Cardiac Rhythm Management Devices Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiac Rhythm Management Devices Market size was valued at USD 18.80 billion in 2022 and is poised to grow from USD 19.83 billion in 2023 to USD 30.44 billion by 2031, at a CAGR of 5.5% during the forecast period (2024-2031)

Cardiac rhythm management device companies should focus on developing affordable products to maximize their sales in developing countries. Currently, countries with developed healthcare infrastructure provide lucrative business scope for new as well as established cardiac rhythm management device providers. Collaborations, new product launches, mergers, and new product approvals are slated to be key strategies for cardiac rhythm management devices market players in the long run.  'Physio-Control, Inc. (Stryker) (US) ', 'BIOTRONIK (Germany) ', 'Schiller (Switzerland) ', 'Medtronic (US) ', 'Abbott (US) ', 'Koninklijke Philips N.V. (Netherlands) ', 'Zoll Medical Corporation (US) ', 'Boston Scientific Corporation (US) ', 'Progetti Srl (Italy) ', 'LivaNova Plc (UK) ', 'Impella (ABIOMED, US) ', 'AngioDynamics, Inc. (US) ', 'MicroPort Scientific Corporation (China) ', 'Edwards Lifesciences Corporation (US) ', 'Getinge AB (Sweden) ', 'Synchrony Medical (US) ', 'Osypka AG (Germany) ', 'Inspire Medical Systems, Inc. (US) ', 'AtriCure, Inc. (US) ', 'Apex Medical (Taiwan) ', 'Biotronik SE & Co. KG (Germany) ', 'VivaSonic Inc. (US)'

Preference for minimally invasive cardiac procedures among patients has increased rapidly and this trend aligns with cardiac rhythm management devices as well. Easy implantation of cardiac rhythm management devices using minimally invasive procedures is projected to favor the demand for cardiac rhythm management devices in the long run.   

Use for Heart Failure Patients: Cardiac rhythm management devices are being used to manage heart failure patients as they are capable of monitoring physiological parameters such as fluid buildup, which can indicate heart failure worsening in patients. This can help medical professionals keep track of cardiac health of patients and provide proper care at the right time to avoid complete heart failure and loss of lives.  

North America is expected to spearhead the global demand for cardiac rhythm management devices across the study period. Growing number of cardiovascular procedures, presence of key cardiac rhythm management device companies, and high healthcare expenditure allow this region to hold sway over others. Moreover, the presence of developed healthcare infrastructure and the availability of favorable reimbursement policies are helping the United States remain the most lucrative market in North America. Canada is also estimated to witness high demand for cardiac rhythm management device in this region going forward. Increasing approval of novel cardiac rhythm management devices and quick adoption of the same also contribute to the high share of North America.  

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cardiac Rhythm Management Devices Market

Report ID: SQMIG35A2577

$5,300
BUY NOW GET FREE SAMPLE